ZELTIQ® Aesthetics, Inc. (Nasdaq: ZLTQ), is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. The Company’s first commercial product, the CoolSculpting® system, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. The technology, based on the scientific principle (Cryolipolysis®) that fat cells are more sensitive to cold that the overlying skin and surrounding tissues, is the subject of more than 120 podium presentations and more than 30 published articles around the world. Drs. Manstein and R. Rox Anderson at the Wellman Center at Massachusetts General Hospital, a teaching affiliate for Harvard Medical School, conducted initial Cryolipolysis research.
Since ZELTIQ’s founding in 2005, the company has strategically grown the CoolSculpting procedure to become the #1 non-invasive body contouring procedure. In the U.S. alone, more than 22.4 million people are interested in the CoolSculpting procedure for fat reduction. It generates unprecedented industry buzz, securing hundreds of headlines annually and leveraging social media presence, generating 3.4 billion consumer impressions and a 97% favorable online brand sentiment rating. CoolSculpting Web sites see over 100,000 global visitors each month, including 25,000 prospective patients utilizing the “Find-a-Physician” locator. ZELTIQ has shipped CoolSculpting systems to over 60 countries worldwide.
In 2014, ZELTIQ was recognized as the #1 medical device company and 24th overall on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies – both public and private – in North America. Technology Fast 500 award winners are selected on percentage fiscal revenue growth from 2009 to 2013. ZELTIQ grew approximately 7,000 percent during this period.
Number One Fastest Growing Medical Device Company